| # | Drug | Count |
|---|---|---|
| 0 | METHOTREXATE SODIUM | 124 |
| 1 | METHOTREXATE | 116 |
| 2 | ADALIMUMAB | 115 |
| 3 | PREDNISONE | 99 |
| 4 | ETANERCEPT | 84 |
| 5 | RITUXIMAB | 74 |
| 6 | INTERFERON BETA-1A | 73 |
| 7 | CYCLOPHOSPHAMIDE | 72 |
| 8 | CYCLOPHOSPHAMIDE FOR INJECTION | 72 |
| 9 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 72 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DINUTUXIMAB | 17 | 0.0198 |
| 1 | THIOTEPA | 20 | 0.0020 |
| 2 | AXICABTAGENE CILOLEUCEL | 13 | 0.0013 |
| 3 | BUPIVACAINE | 12 | 0.0013 |
| 4 | INTERFERON BETA-1B | 17 | 0.0009 |
| 5 | ADALIMUMAB-FKJP | 37 | 0.0008 |
| 6 | ADALIMUMAB-AATY | 38 | 0.0008 |
| 7 | DURVALUMAB | 16 | 0.0007 |
| 8 | ADALIMUMAB-ADAZ | 38 | 0.0007 |
| 9 | TEMOZOLOMIDE | 13 | 0.0006 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 207 |
| 1 | Tumor Necrosis Factor Blocker [EPC] | 174 |
| 2 | Folate Analog Metabolic Inhibitor [EPC] | 116 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 104 |
| 4 | Alkylating Drug [EPC] | 102 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 96 |
| 6 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 82 |
| 7 | Platinum-based Drug [EPC] | 75 |
| 8 | Interferon beta [EPC] | 74 |
| 9 | Integrin Receptor Antagonist [EPC] | 63 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 17 | 0.0157 |
| 1 | Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor [EPC] | 1 | 0.0096 |
| 2 | Interleukin-5 Antagonist [EPC] | 5 | 0.0073 |
| 3 | CD19-directed Cytolytic Antibody [EPC] | 6 | 0.0070 |
| 4 | CD4-directed Blocking Antibody [EPC] | 1 | 0.0019 |
| 5 | Provitamin D2 Compound [EPC] | 49 | 0.0016 |
| 6 | Guanylate Cyclase-C Agonist [EPC] | 3 | 0.0014 |
| 7 | CD19-directed Chimeric Antigen Receptor [EPC] | 13 | 0.0013 |
| 8 | Gamma Secretase Inhibitor [EPC] | 1 | 0.0011 |
| 9 | Type I Interferon Receptor Antagonist [EPC] | 2 | 0.0010 |